{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:43:06Z","timestamp":1790764986967,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.tmrv.2007.09.001","type":"journal-article","created":{"date-parts":[[2007,12,10]],"date-time":"2007-12-10T21:31:23Z","timestamp":1197322283000},"page":"1-34","source":"Crossref","is-referenced-by-count":82,"title":["Proceedings of a Consensus Conference: Pathogen Inactivation\u2014Making Decisions About New Technologies"],"prefix":"10.1016","volume":"22","author":[{"given":"Kathryn E.","family":"Webert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Cserti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Hannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Pavenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Pendergrast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris A.","family":"Blajchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2007.09.001_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1423-0410.2007.00937.x","article-title":"Pathogen inactivation: making decisions about new technologies\u2014Preliminary report of a consensus conference","volume":"93","author":"Klein","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib2","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1111\/j.1537-2995.2006.00957.x","article-title":"Transfusion-transmitted viral infections: Building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis","volume":"46","author":"Busch","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib3","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1111\/j.1537-2995.2006.01010.x","article-title":"Managing threats rather than risks in blood transfusion: Robust design for a complex system","volume":"46","author":"Murphy","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1128\/CMR.11.3.480","article-title":"Dengue and dengue hemorrhagic fever","volume":"11","author":"Gubler","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.tmrv.2007.09.001_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa044333","article-title":"West Nile virus among blood donors in the United States, 2003 and 2004","volume":"353","author":"Stramer","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2007.09.001_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1046\/j.1537-2995.1998.38198141508.x","article-title":"Current status of solvent\/detergent-treated frozen plasma","volume":"38","author":"Klein","year":"1998","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.5858\/2007-131-719-PITDSF","article-title":"Pathogen inactivation: The definitive safeguard for the blood supply","volume":"131","author":"Bryant","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.tmrv.2007.09.001_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/tmrv.2002.29405","article-title":"Virus inactivation in blood components by photoactive phenothiazine dyes","volume":"16","author":"Wagner","year":"2002","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2007.09.001_bib9","first-page":"7","article-title":"Photochemical inactivation of viruses with psoralens: an overview","volume":"18","author":"Hanson","year":"1992","journal-title":"Blood Cells"},{"key":"10.1016\/j.tmrv.2007.09.001_bib10","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V91.6.2180","article-title":"Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA","volume":"91","author":"Grass","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2007.09.001_bib11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1203\/00006450-198303000-00014","article-title":"Short communication. Photochemical reactions of riboflavin: Covalent binding to DNA and to poly (dA). poly (dT)","volume":"17","author":"Ennever","year":"1983","journal-title":"Pediatr Res"},{"key":"10.1016\/j.tmrv.2007.09.001_bib12","doi-asserted-by":"crossref","first-page":"13221","DOI":"10.1016\/S0021-9258(19)38640-5","article-title":"8-Hydroxydeoxyguanosine formation at the 5\u2032 site of 5\u2032-GG-3\u2032 sequences in double-stranded DNA by UV radiation with riboflavin","volume":"268","author":"Ito","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tmrv.2007.09.001_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1473-0502(01)00116-1","article-title":"Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application","volume":"25","author":"Corash","year":"2001","journal-title":"Transfus Apheresis Sci"},{"key":"10.1016\/j.tmrv.2007.09.001_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1537-2995.2002.00020.x","article-title":"Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: Preclinical studies","volume":"42","author":"Purmal","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib15","author":"McQueen"},{"key":"10.1016\/j.tmrv.2007.09.001_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0037-1963(01)90119-2","article-title":"Preclinical safety of a nucleic acid-targeted Helinx compound: A clinical perspective","volume":"38","author":"Ciaravino","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib17","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1046\/j.1537-2995.2003.00544.x","article-title":"The role of toxicology assessment in transfusion medicine","volume":"43","author":"Ciaravino","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib18","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1046\/j.1537-2995.2003.00497.x","article-title":"Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies","volume":"43","author":"Chapman","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1423-0410.2003.00351.x","article-title":"Preclinical safety profile of plasma prepared using the INTERCEPT Blood System","volume":"85","author":"Ciaravino","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1191\/096032701718120319","article-title":"Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets","volume":"20","author":"Ciaravino","year":"2001","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2007.07.004","article-title":"Exposure of hematopoietic stem cells to ethylene oxide during processing represents a potential carcinogenic risk for transplant recipients","author":"Butterworth","year":"2007","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib22","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.V79.3.826.826","article-title":"Solvent\/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma","volume":"79","author":"Horowitz","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2007.09.001_bib23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1423-0410.1998.tb05474.x","article-title":"Solvent\/detergent treatment of human plasma\u2014A very robust method for virus inactivation. Validated virus safety of OCTAPLAS","volume":"74","author":"Biesert","year":"1998","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1537-2995.1997.37497265344.x","article-title":"Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light","volume":"37","author":"Lin","year":"1997","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1423-0410.1991.tb00907.x","article-title":"Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light","volume":"60","author":"Lambrecht","year":"1991","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1423-0410.2000.tb00065.x","article-title":"The use of riboflavin for the inactivation of pathogens in blood products","volume":"78","author":"Goodrich","year":"2000","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/1098-1101(2000)15:3<169::AID-JCA2>3.0.CO;2-R","article-title":"Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent\/detergent-treated plasma: Is its decreased protein S activity clinically related to their development of deep venous thromboses?","volume":"15","author":"Flamholz","year":"2000","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.tmrv.2007.09.001_bib28","article-title":"A cluster of intra-operative deaths in a liver transplant center associated with the use of solvent\/detergent plasma","author":"Coignard","year":"2001"},{"key":"10.1016\/j.tmrv.2007.09.001_bib29","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1046\/j.1365-2141.2003.04360.x","article-title":"Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura","volume":"121","author":"Yarranton","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib30","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1537-2995.1999.39111227.x","article-title":"A randomized trial of solvent\/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation","volume":"39","author":"Williamson","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib31","first-page":"887","article-title":"Efficacy of SD-treated plasma during liver transplantation (reply)","volume":"40","author":"Williamson","year":"2000","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-3148.2006.00672.x","article-title":"Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe?","volume":"16","author":"Salge-Bartels","year":"2006","journal-title":"Transfus Med"},{"key":"10.1016\/j.tmrv.2007.09.001_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.transci.2006.08.008","article-title":"A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment","volume":"35","author":"Heger","year":"2006","journal-title":"Transfus Apheresis Sci"},{"key":"10.1016\/j.tmrv.2007.09.001_bib34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/01.moh.0000137915.88478.23","article-title":"Solvent\/detergent-treated plasma: Composition, efficacy, and safety","volume":"11","author":"Hellstern","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2141.2004.04973.x","article-title":"Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials","volume":"126","author":"Stanworth","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1423-0410.1999.7740210.x","article-title":"Clinical tolerance of methylene blue virus\u2013inactivated plasma. A randomized crossover trial in 12 healthy human volunteers","volume":"77","author":"Simonsen","year":"1999","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib37","first-page":"23S","article-title":"Prospective randomized and controlled trial on solvent\/detergent plasma versus methylene blue light inactivated plasma","volume":"39","author":"Wieding","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.0042-9007.2004.00506.x","article-title":"Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura","volume":"86","author":"Varez-Larran","year":"2004","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1365-2141.2001.02991.x","article-title":"Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura","volume":"114","author":"de la","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib40","first-page":"41","article-title":"Methylene blue photoinactivated plasma (MBPIP) vs fresh frozen plasma (FFP) in the treatment of idiopathic thrombotic thrombocytopenic purpura (TTP): a multicentre prospective-cohort study","volume":"93","author":"del Rio-Garma","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib41","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1046\/j.1537-2995.2001.41121548.x","article-title":"Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate","volume":"41","author":"Atance","year":"2001","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib42","first-page":"183","article-title":"Coagulation function in fresh frozen plasma prepared with two photochemical treatment methods","volume":"91","author":"Osselaer","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1423-0410.2007.00898.x","article-title":"Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience","volume":"92","author":"Politis","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib44","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0887-7963(96)80006-X","article-title":"Clinical studies with solvent detergent\u2013treated products","volume":"10","author":"Pehta","year":"1996","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2007.09.001_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-3148.2006.00626.x","article-title":"Solvent-detergent plasma: Use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies","volume":"16","author":"Chekrizova","year":"2006","journal-title":"Transfus Med"},{"key":"10.1016\/j.tmrv.2007.09.001_bib46","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2004-03-0930","article-title":"Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease","volume":"107","author":"Mintz","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2007.09.001_bib47","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/j.1537-2995.2006.00959.x","article-title":"A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura","volume":"46","author":"Mintz","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/jama.282.4.329","article-title":"Update of cost-effectiveness analysis for solvent-detergent\u2013treated plasma","volume":"282","author":"Jackson","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2007.09.001_bib49","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1537-2995.1999.39050479.x","article-title":"Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma","volume":"39","author":"Pereira","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1423-0410.2003.00329.x","article-title":"Cost-effectiveness of solvent\/detergent-treated fresh-frozen plasma","volume":"85","author":"Riedler","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1423-0410.2006.00761.x","article-title":"Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects","volume":"90","author":"Goodrich","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib52","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1537-2995.2005.00202.x","article-title":"Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction","volume":"45","author":"AuBuchon","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib53","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.0041-1132.2004.04145.x","article-title":"Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light","volume":"44","author":"Snyder","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1056\/NEJM197207272870401","article-title":"The bleeding time as a screening test for evaluation of platelet function","volume":"287","author":"Harker","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2007.09.001_bib55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1537-2995.2006.00791.x","article-title":"Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia","volume":"46","author":"Slichter","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib56","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2003-12-4443","article-title":"Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial","volume":"104","author":"McCullough","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2007.09.001_bib57","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood-2002-03-0932","article-title":"Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial","volume":"101","author":"van Rhenen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2007.09.001_bib58","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/j.1537-2995.2005.00550.x","article-title":"Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set","volume":"45","author":"Janetzko","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib59","first-page":"6S","article-title":"Influence of gender and collection order on radiolabeled red blood cell recovery","volume":"35","author":"Pickard","year":"1995","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib60","author":"US Food and Drug Administration"},{"key":"10.1016\/j.tmrv.2007.09.001_bib61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1537-2995.2002.00021.x","article-title":"Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: A phase I clinical study","volume":"42","author":"AuBuchon","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib62","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/j.1537-2995.2006.00973.x","article-title":"Viability of red cells prepared with S-303 pathogen inactivation treatment","volume":"46","author":"Rios","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib63","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1537-2995.2005.00583.x","article-title":"Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: A phase III clinical trial in cardiac surgery patients","volume":"45","author":"Benjamin","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib64","article-title":"Pathogen inactivation","author":"Wagner","year":"2005"},{"key":"10.1016\/j.tmrv.2007.09.001_bib65","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1046\/j.1537-2995.2000.40111285.x","article-title":"Universal RBCs","volume":"40","author":"Lublin","year":"2000","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib66","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tmrv.2004.06.005","article-title":"Progress in modulating the RBC membrane to produce transfusable universal\/stealth donor RBCs","volume":"18","author":"Garratty","year":"2004","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2007.09.001_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21307\/immunohematology-2019-646","article-title":"In vitro reactions with red blood cells that are not due to blood group antibodies: A review","volume":"14","author":"Garratty","year":"1998","journal-title":"Immunohematol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib68","doi-asserted-by":"crossref","first-page":"112a","DOI":"10.1182\/blood.V104.11.382.382","article-title":"Antibody formation to S-303\u2013treated RBCs in setting of chronic RBC transfusion","volume":"104","author":"Conlan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2007.09.001_bib69","first-page":"116A","article-title":"A modified process for preparation of S-303 RBCs for pathogen inactivation substantially reduces potential for reactivity","volume":"46","author":"North","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib70","first-page":"138","article-title":"Modification of the S-303 RBC pathogen inactivation process results in normal S-303 RBC viability in rabbits hyper-immunized to S-303 [abstract]","volume":"89","author":"Stassinopoulos","year":"2005","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tmrv.2006.05.002","article-title":"Serious hazards of transfusion: a decade of hemovigilance in the UK","volume":"20","author":"Stainsby","year":"2006","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2007.09.001_bib72","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1423-0410.2003.00313.x","article-title":"An international study of the performance of sample collection from patients","volume":"85","author":"Dzik","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib73","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.0958-7578.2004.0488.x","article-title":"Current performance of patient sample collection in the UK","volume":"14","author":"Murphy","year":"2004","journal-title":"Transfus Med"},{"key":"10.1016\/j.tmrv.2007.09.001_bib74","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1309\/C6U7VP87GC030WMG","article-title":"Nearly two decades using the check-type to prevent ABO incompatible transfusions: One institution's experience","volume":"126","author":"Figueroa","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib75","doi-asserted-by":"crossref","first-page":"289a","DOI":"10.1182\/blood.V108.11.970.970","article-title":"Impact of a policy to use only group O red cell transfusions for recipients with fewer-than-twice established ABO types: A feasible means to reduce potential ABO incompatible transfusion errors","volume":"108","author":"Cserti","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2007.09.001_bib76","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1537-2995.2005.04365.x","article-title":"High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes","volume":"45","author":"Denomme","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib77","article-title":"Update on bacterial contamination","author":"Vostal","year":"2005"},{"key":"10.1016\/j.tmrv.2007.09.001_bib79","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1172\/JCI29499","article-title":"Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation","volume":"116","author":"Zarbock","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tmrv.2007.09.001_bib80","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood-2004-06-2282","article-title":"Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation","volume":"105","author":"Pitchford","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2007.09.001_bib81","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1189\/jlb.72.3.455","article-title":"Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion","volume":"72","author":"Kupatt","year":"2002","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib82","author":"Benjamin","year":"2006"},{"key":"10.1016\/j.tmrv.2007.09.001_bib83","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything all right? Interpreting zero numerators","volume":"249","author":"Hanley","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2007.09.001_bib84","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1537-2995.2005.00639.x","article-title":"Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: The SPRINT trial","volume":"45","author":"Snyder","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib85","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2807\/esm.10.02.00522-en","article-title":"Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: Risk of virus transmission and the impact of nucleic acid amplification testing","volume":"10","author":"Offergeld","year":"2005","journal-title":"Euro Surveill"},{"key":"10.1016\/j.tmrv.2007.09.001_bib86","unstructured":"German haemovigilance, Paul-Ehrlich-Institute. 2007."},{"key":"10.1016\/j.tmrv.2007.09.001_bib87","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1537-2995.2007.01166.x","article-title":"Bacterial contamination of platelet concentrates: Results of a prospective multicenter study comparing pooled whole blood\u2013derived platelets and apheresis platelets","volume":"47","author":"Schrezenmeier","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib88","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1423-0410.2000.7840209.x","article-title":"Photochemical inactivation of bacteria and HIV in buffy-coat\u2013derived platelet concentrates under conditions that preserve in vitro platelet function","volume":"78","author":"Knutson","year":"2000","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib89","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/j.1537-2995.2005.00587.x","article-title":"White blood cell\u2013reactive antibodies are undetectable in solvent\/detergent plasma","volume":"45","author":"Sachs","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib90","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.transci.2006.02.004","article-title":"Update on pathogen reduction technology for therapeutic plasma: An overview","volume":"35","author":"Solheim","year":"2006","journal-title":"Transfus Apheresis Sci"},{"key":"10.1016\/j.tmrv.2007.09.001_bib91","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tmrv.2003.12.002","article-title":"Economic analyses of blood safety and transfusion medicine interventions: A systematic review","volume":"18","author":"Custer","year":"2004","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2007.09.001_bib92","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1423-0410.2002.00198.x","article-title":"Pharmaco-economics of blood transfusion safety: Review of the available evidence","volume":"83","author":"van Hulst","year":"2002","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib93","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jama.1994.03520150078041","article-title":"Safety and cost-effectiveness of solvent-detergent\u2013treated plasma. In search of a zero-risk blood supply","volume":"272","author":"AuBuchon","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2007.09.001_bib94","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1046\/j.1423-0410.2003.00307_1.x","article-title":"Solvent-detergent\u2013treated plasma may be cost-effective","volume":"84","author":"Riedler","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib95","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/S0149-2918(03)80288-6","article-title":"Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States","volume":"25","author":"Bell","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.tmrv.2007.09.001_bib96","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1532\/IJH97.04131","article-title":"Economics of pathogen inactivation technology for platelet concentrates in Japan","volume":"80","author":"Staginnus","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1016\/j.tmrv.2007.09.001_bib97","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1537-2995.2006.00828.x","article-title":"Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands","volume":"46","author":"Janssen","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib98","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-3148.2005.00609.x","article-title":"Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands","volume":"15","author":"Postma","year":"2005","journal-title":"Transfus Med"},{"key":"10.1016\/j.tmrv.2007.09.001_bib99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-3148.2006.00644.x","article-title":"Assessment of the economic value of the INTERCEPT blood system in Belgium","volume":"16","author":"Moeremans","year":"2006","journal-title":"Transfus Med"},{"key":"10.1016\/j.tmrv.2007.09.001_bib100","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1537-2995.2004.03275.x","article-title":"Positively charged porphyrins: A new series of photosensitizers for sterilization of RBCs","volume":"44","author":"Trannoy","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib101","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1423-0410.2006.00791.x","article-title":"Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)\u2013photoinactivation","volume":"91","author":"Trannoy","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib102","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1423-0410.2006.00810.x","article-title":"Photoinactivation of Leishmania donovani infantum in red cell suspensions by a flexible thiopyrylium sensitizer","volume":"91","author":"Wagner","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib103","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1423-0410.2006.00864.x","article-title":"In vivo recovery and survival of red cells after photodynamic treatment with thiopyrylium and red light using a canine model","volume":"92","author":"Skripchenko","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2007.09.001_bib104","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1537-2995.2006.00703.x","article-title":"Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties","volume":"46","author":"Skripchenko","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1537-2995.2007.01108.x","article-title":"Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services","volume":"47","author":"O'Brien","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2007.09.001_bib106","series-title":"The structure of scientific revolutions","author":"Kuhn","year":"1970"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796307000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796307000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:10:40Z","timestamp":1737641440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796307000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0887796307000843"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2007.09.001","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}